Mediar Therapeutics is pioneering a novel approach to treating fibrosis by targeting myofibroblasts, the key pathogenic cells responsible for scarring and disease progression. The company focuses on a new class of fibrotic mediators that activate these myofibroblasts. By developing first-in-class antibodies that neutralize these proteins, Mediar aims to slow down fibrosis and promote tissue regeneration. The fibrotic mediators are measurable in plasma and correlate with disease severity, suggesting their potential for precision medicine in treating various fibrotic conditions.

The company is advancing several clinical candidates, including MTX-463 and MTX-474, which are designed to neutralize specific signaling pathways involved in fibrosis. MTX-463 targets the WISP1 protein, which plays a significant role in fibrosis progression, while MTX-474 focuses on EphrinB2, implicated in tissue remodeling and myofibroblast activation. Both candidates are in various stages of clinical development, with studies planned for conditions such as Idiopathic Pulmonary Fibrosis and Systemic Sclerosis. Mediar's robust scientific foundation supports the exploration of additional indications, including hepatic, renal, and cardiac fibrosis, highlighting their commitment to addressing challenging fibrotic diseases with limited therapeutic options.

United States

Mediar Therapeutics is a biotechnology company pioneering a new approach to fibrosis treatment that halts the disease at a different source – the fibrotic mediators that drive disease progression. 

Mediar was founded based on a deep understanding of the complex science underlying fibrosis onset and progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar is derisking the path forward for fibrosis therapies in clinical development. 

For more information, contact info@mediartx.com 

Mediar Therapeutics

Company Details